The diagnosis of her2 breat cancer primarily relies on standardized sample processing procedures. According to the guidelines of the American Society of Clinical Oncology (ASCO), breast cancer biopsy tissues should be fixed in 10% neutral buffered formalin within 60 minutes after surgical resection, and the fixation time should be strictly controlled within the range of 6 to 72 hours. Studies have shown that deviating from this standard can lead to a 25% increase in the false negative rate of HER2 testing, especially for samples fixed for less than 8 hours, the integrity of antigen preservation drops by 40%.
IHC testing is stained with FDA-approved clonal antibodies. The most commonly used 4B5 antibody reagent at present can achieve the best staining effect when diluted at a concentration of 1:50 on an automated staining platform and incubated at 37 ° C for 32 minutes. Data from a multi-center study in 2018 showed that the sensitivity of this antibody in detecting HER2 protein expression reached 98.7%, the specificity was 92.3%, and the overall coincidence rate with FISH detection results was 95.6%.
The result interpretation followed the standardized scoring system established by ASCO/CAP. Pathologists score 0 to 3+ based on the intensity and integrity of cell membrane staining: less than 10% of tumor cells show incomplete weak staining and are rated as 0 points. More than 10% of the cells showed weak to moderate intact membrane staining and were rated as 1+. More than 10% of the cells showed moderate to intense intact membrane staining and were rated as 2+. Cells with more than 10% showing strong and intact membrane staining were rated as 3+. Statistics show that the consistency κ value among raters must reach above 0.85 to meet the quality control standards.
FISH validation must be conducted for borderline cases of IHC 2+. Data shows that approximately 20% of IHC 2+ cases are confirmed as HER2 positive by FISH testing, and the effective rate of targeted therapy for these patients can reach 76%. The latest guidelines for 2023 require that FISH testing simultaneously assess the HER2/CEP17 ratio and single copy number. A ratio of ≥2.0 and an average copy number of ≥4.0 signal/cell is defined as positive, while a ratio of <2.0 but a copy number of ≥6.0 signal/cell is also determined as positive.
The quality control system ensures the accuracy of testing. The laboratory needs to participate in the annual proficiency testing, and the pass rate of the external quality assessment of HER2 IHC testing is required to reach more than 90%. Each test batch must include a positive control (tissue sections with a known score of 3+) and a negative control (tissue sections with a known score of 0), and the coincidence rate of the control samples must reach 100%. Data shows that after the implementation of this quality control system, the repeatability of HER2 detection has increased from 85% to 97.8%.
The application of new technologies enhances diagnostic accuracy. The digital pathology system uses artificial intelligence algorithms to assist in interpretation, increasing the correlation between IHC scores and FISH results to 0.93. A prospective study in 2024 shows that AI-assisted systems have reduced the diagnosis time by 40% and lowered the misdiagnosis rate of critical cases to below 5%. These technological advancements provide an important guarantee for the precise diagnosis of her2 breast cancer.